The National Agency for Food and Drug Administration and Control says its 5+5 policy and import Ceiling List have contributed to increased local production of medicines and medical devices in Nigeria.
Director-General Mojisola Adeyeye said the number of pharmaceutical manufacturing companies had increased from 174 to 190 as policy measures encouraged firms to establish or expand domestic facilities.
She spoke at the Lagos Chamber of Commerce and Industry’s Invest in Nigeria Conference.
Adeyeye said 28 companies had been newly developed or retrofitted and 16 new facilities had been established, bringing the total affected by the initiative to 44.
NAFDAC linked those developments to what it described as a 25 per cent increase in local manufacturing.
The 5+5 policy was introduced in 2019 to phase out imports of selected medicines that Nigerian manufacturers were considered capable of producing locally.
Companies affected by the restrictions are expected either to establish local production or use qualified Nigerian contract manufacturers.
The Ceiling List later expanded the number of products restricted from importation from nine in 2020 to 36.
Adeyeye said President Bola Tinubu’s executive measures providing zero tariffs, excise duties and Value Added Tax on selected machinery, equipment and raw materials for healthcare manufacturing had also supported investment.
As of June 2026, she said 176 pharmaceutical companies had undergone facility-layout reviews, comprising 70 existing companies and 106 new entrants.
NAFDAC said imports of products covered by the two policy categories had fallen by about 70 per cent.
The agency also said the balance between imported and locally manufactured pharmaceutical products had shifted from about 70:30 in 2019 to 50:50 in 2025.
Contract manufacturing partnerships increased from 10 companies in 2019 to 87 in 2026, according to the regulator.
Adeyeye said 37 existing manufacturers were undergoing construction or upgrades, while 28 had completed works and were operational.
She also reported new investment in pharmaceutical, medical-device and in-vitro diagnostic manufacturing.
NAFDAC said the longer-term objective was to reduce dependence on imported medical products, encourage technology transfer and strengthen domestic manufacturing capacity.